Remix Therapeutics

Market position

Remix positions itself within RNA-targeted drug discovery, pursuing small molecules rather than oligonucleotides or biologics to modulate RNA processing. Third-party commentary frames the company as part of a broader industry shift toward RNA-targeted therapeutics, with pharma partnerships from Roche and Johnson & Johnson cited as external validation of the platform. The company describes REM-422 as a first-in-class MYB mRNA degrader, and notes there are no approved treatment options for MYB-driven adenoid cystic carcinoma.

Stated differentiators include the REMaster platform's ability to identify large numbers of novel exon target sites via bioinformatics and machine learning, multiplexed high-throughput screening across dozens of targets simultaneously, a purpose-built chemical library oriented toward RNA processing mechanisms, an orally available small-molecule modality applied to targets typically pursued with oligonucleotides or biologics, and clinical validation from first-in-human data on a platform-derived molecule against MYB.

Technology

The REMaster drug discovery platform is built on three stated pillars. Data science and bioinformatics use an internal transcriptome database and machine learning to identify modulatable RNA target sites; the company states it has identified more than 1.6 million novel exon targets in the mRNA degradation space, which it describes as 25-fold more than the largest public database. Biology and biomolecular sciences apply a proprietary genetic toolkit for functional target validation plus multiplexed cell-based high-throughput screens that test dozens of targets in parallel. Medicinal and computational chemistry draw on a purpose-built proprietary chemical library enriched for compounds that interact with RNA processing mechanisms. Outputs are orally available small molecules, including mRNA degraders such as REM-422, that reduce target mRNA and protein expression.

Go-to-market

Remix advances wholly owned candidates through company-sponsored clinical trials while entering discovery and license collaborations with large pharma partners that assume development and commercialization for partnered programs. The company communicates progress through press releases, medical and investor conference presentations (2026 ASCO Annual Meeting oral presentation; Guggenheim Second Annual Healthcare Innovation Conference in late 2025), and regulatory milestones such as FDA Fast Track designation.

Patients and treating clinicians in oncology indications driven by difficult-to-drug targets - including adenoid cystic carcinoma, acute myeloid leukemia/myelodysplastic syndromes and other MYB- and MYC-dependent cancers - with stated future expansion into neurodegenerative and CNS disease. Large pharmaceutical companies are counterparties for discovery and development collaborations.

Geography

Headquartered in Watertown, Massachusetts, United States (100 Forge Road, Suite 400, Watertown, MA 02472 per one aggregator). Employees are reported as located in North America only.

History

Company statements place the launch in 2020. Third-party sources report multi-year discovery collaborations with Johnson & Johnson Innovative Medicine announced in 2022 and a January 2024 collaboration and license agreement with Roche that included $30 million upfront, up to $12 million in near-term milestones, up to roughly $1 billion in total milestones, and tiered royalties; the Roche deal was announced alongside the closing of a $60 million financing intended to support REM-422's move into the clinic. First clinical results for REM-422 were shared in 2025, described by the company as the first human data from a molecule generated on its REMaster platform. In March 2026 the FDA granted Fast Track designation to REM-422 in recurrent, metastatic or unresectable adenoid cystic carcinoma. Final Phase 1 dose-escalation results from the Phase 1/2 ARIA study were presented at the 2026 ASCO Annual Meeting, and in June 2026 the company announced a merger agreement with Passage Bio plus a $100 million private placement.

Risks & controversies

Sources contain inconsistent basic facts about the company, including founding year (2018 in aggregator profiles versus a stated 2020 launch on the company site), employee count (52 versus 51-200 versus an implausible 10,000+ listing), and total funding raised ($271.0M versus $60M across aggregators), indicating unreliable third-party data. Business risks evident from the sources include a pipeline concentrated on a single clinical asset, REM-422, which remains in Phase 1/2 with no approved products; dependence on partners Roche and Johnson & Johnson for milestone and royalty economics; and execution and closing risk associated with the announced Passage Bio merger and associated private placement.